> A leading hypothesis is that these variants, characterized by a large number of nonsynonymous mutations, originated within individuals with long durations of infection during which the virus was subject to prolonged immune pressure (7, 8), and that this was potentially facilitated by the within-host emergence of deletions (49). [0]
Consequently, some have suggested that monitoring for new strains might focus on such patients as a way to predict future adaptations in the wild, as scientist have observed some mutations re-occurring within immunocompromised individuals. So it might be possible to predict some mutations.
[0] : https://www.nytimes.com/2021/03/15/health/coronavirus-varian...
[1] : https://www.science.org/doi/full/10.1126/science.abg0821
And yes, there are virologists who are studying the mutation-space of the virus and are planning a vaccine regimen which targets all possible mutations of SARS-CoV-2. Check out this absolutely terrific lecture by Paul Bieniasz about his work on exploring the mutation space of SARS-CoV-2: https://www.youtube.com/watch?v=LIcaSqQFrX0
It isn’t clear exactly what is going to happen, but as more people get vaccinated and natural immunity and the variants continue to evolve the situation might change a lot or become unnoticeable.
I would love to see an epidemic expert comment on the long term evolutionary effects of different mitigation strategies which might differ in preferences than short term trying to reduce number of infections.
Those evolutionary pressures relate to transmissibility. Basically, a virus that kills its host before it can spread doesn't spread very far at all.
SARS-CoV-2's defining feature of asymptomatic spread decouples this and so far hasn't led to weakening – indeed, Delta is both substantially more transmissible and more likely to cause severe disease and death.
> Research early in the pandemic suggested that the rate of asymptomatic infections could be as high as 81%. But a meta-analysis published last month, which included 13 studies involving 21,708 people, calculated the rate of asymptomatic presentation to be 17%. The analysis defined asymptomatic people as those who showed none of the key COVID-19 symptoms during the entire follow-up period, and the authors included only studies that followed participants for at least seven days.
There are many more I've read where the authors have tried to quantify asymptomatic spread and been found wanting (studies on children are particularly enlightening). I wouldn't be surprised if the final figure ends up being very close to, if not, zero, though we're still in the clutches of the initial panic so I suspect those findings to take time due more to social resistance than the frictions involved in actual science.
[1] https://www.nature.com/articles/d41586-020-03141-3?error=coo...
For example[1]:
> We determined secondary attack rates (SAR) among close contacts of 59 asymptomatic and symptomatic coronavirus disease case-patients by presymptomatic and symptomatic exposure. We observed no transmission from asymptomatic case-patients and highest SAR through presymptomatic exposure.
"Presymptomatic transmission" is asymptomatic transmission. Whether the infection itself becomes symptomatic later (which, as you've referenced, the research strongly suggests will happen) is of no relevance to the discussion.
> Whether the infection itself becomes symptomatic later (which, as you've referenced, the research strongly suggests will happen) is of no relevance to the discussion.
What's actually irrelevant is talking about asymptomatic infections - defined as those which do not become symptomatic - as if they do become symptomatic. Again, I'm yet to find a paper that does this. Whether or not an infection is more likely to become symptomatic or not is not relevant here, nor did I make reference to any such likelihood, because it's not relevant.
I can't tell if you're quibbling because you don't want to accept a minor correction or because you haven't bothered to read any of the literature.
So if the ancestral strain + variants all cannot spread epidemically any more due to the build up of immunity in the population, then a strain which achieves immune escape and an R0 of > 1.0 would be favored even though the virus might be much less "fit" and less virulent in a totally naive population.
Clearly though the major adaptation is going to be on the human side with most of the population eventually acquiring T-cells, which will greatly decrease the virulence going forwards.
It appears that COVID-19 can also enter cells (these would be immune cells that came to 'help') via so called Fc-pathway.
Therefore allow the virus to multiply even more
"... In addition to viral entry via ACE2, antibodies against coronavirus spike proteins (anti-spike-S-IgG) can induce antibody-dependent enhancement (ADE) of viral entry via type II Fcγ receptors. ..." [1]
https://www.science.org/content/blog-post/new-antibody-depen...
I can't flag you, but someone else really should since your followup is completely disingenuous.
Perhaps, it is time to relinquish the presumptions of moral superiority -- and just discuss technical details without the drama ...
I am saying that you wrote does not cover full spectrum of how the virus replicates, therefore your comment does illuminate the complexity that's present in interaction with our immune system. Which includes, according to the NIH paper I referenced, antibody-dependent-enhancement (ADE).
> However, using monkey and mouse models of SARS-CoV-2 infection, none of the in vitro infection-enhancing Abs enhanced SARS-CoV-2 virus replication or infectious virus in the lung in vivo. Three of 46 monkeys had lung pathology or bronchoalveolar lavage (BAL) cytokine levels greater than controls. However, repeat studies with dose ranges of in vitro enhancing Abs did not increase lung pathology. Thus, in vitro infection-enhancing RBD and NTD Abs controlled virus in vivo and was rarely associated with enhanced lung pathology. [1]
You're interjecting it because you want to talk about it because you're an antivaxxer.
It has no relevance outside of some narrow understanding of what happens during severe COVID itself and the mechanism behind why some people get very sick and most people do not.
And you're practicing sealioning acting like you're just innoccently interjecting.
That's because the vaccines don't effectively stop the spread of SARS2. This is one of the great lies still being shoveled on the public - despite the facts that prove otherwise.
See: Britain has a lot more cases per capita than the US, despite their high vaccination rates and more aggressive lock-down & restrictive measures taken.
Or see: the New England states with high vaccination rates and a recent record surge in cases.
Or see: Israel's recent epic case surge despite their very high vaccination rate.
The vaccines dramatically reduce mortality and that's the primary reason most people should get the jab. There's zero evidence so far that we can actually stop SARS2 via vaccine. It doesn't make sense to be forced to live in bomb shelters forever as eg Australia is doing, that's idiotic and tyrannical. What matters isn't the case counts, it's the number of deaths that matter and Britain's high vaccination rate is doing its job there for example.
As a resident of New England, I've been expecting a fall surge for a while. In the north, we're all shutting windows and turning on our furnaces at night, which means much worse ventilation. The afternoons are still warm enough to socialize outside, but that will start to change in November. Followed by holiday travel. And we still have towns with low vaccination rates.
Our absolute numbers are still fairly low in many places, and we don't have people lined up in the corridors of the local hospitals.
> What matters isn't the case counts, it's the number of deaths that matter
I actually think that severe illness counts are important, too. I'll make some sacrifices to avoid hospitalization or merely being incapacitated for a couple weeks.
Perhaps you could furnish us with some examples of such viruses? Every virus I can think of certainly hasn't weakened over time.
Of course, this means that most breakthrough infections are delta.
I don't see why rate of adaption would stay consistent with the early stages of a new virus in later stages.
I don't see how you conclude the virus adapted after 18 months due to six variants of concern existing. Especially because existing solutions are still very effective with the new variants, even if its somewhat of a decline. Even if you accept that as "adaption" its still a sample size of 1.
Are we going to get to a situation like the annual Flu vaccine, where it is tested and released in (what I'm guessing) less than a year? Otherwise, it seems like we'll be chasing this virus with outdated solutions forever. Moderna and Pfizer are both currently testing a vaccine that is specific to Delta, but by the time it's approved (my guess: January/February) the current wave will be long behind us.